SynthesisBMC pregnancy and childbirth2025
Association of antidepressant use during pregnancy and pregnancy-induced hypertension: a systematic review and meta-analysis.
Synthesis in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between maternal depressive symptoms during pregnancy and the risk of preeclampsia: a meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Placental Pathophysiology and Developmental Programming of Adult Cardiometabolic Risk: A Narrative Review of Pregnancy Exposures.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Beyond the 'Pregnancy Black Box': a global roadmap for artificial intelligence-driven pharmacogenomics in maternal-neonatal health.The pharmacogenomics journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe association between antenatal antidepressant use and pregnancy-induced hypertension (GH/PE) remains controversial, with conflicting evidence on whether depression itself confounds this risk.
methodsWe searched PubMed, Web of Science, Medline, Embase, Cochrane Library, and the China National Knowledge Infrastructure electronic databases from inception to Dec. 31, 2024. Eligibility criteria for selecting studies are randomized trials, cohort studies, and case-control studies exploring the association between antidepressant use during pregnancy and pregnancy-induced hypertension. Two reviewers extracted data and assessed quality. Outcomes were expressed as odds ratios with 95% confidence intervals.
resultsSeventeen observational studies were analyzed, indicating a potential link between antidepressant use in pregnancy and an elevated risk of gestational hypertension/preeclampsia (GH/PE). Pooled odds ratios (ORs) stratified by drug class demonstrated significant associations for: Selective serotonin reuptake inhibitors (OR = 1.34; 95% CI: 1.14-1.58); Serotonin-norepinephrine reuptake inhibitors (OR = 1.94; 95% CI: 1.40-2.70); Tricyclic antidepressants (OR = 2.00; 95% CI: 1.32-3.04). Following adjustment for depression as a confounding variable, sensitivity analysis indicated: SNRIs maintained significant association with GH/PE (adjusted OR = 1.53; 95% CI: 1.25-1.88); SSRIs showed no significant risk (adjusted OR = 1.03; 95% CI: 0.97-1.10); TCAs lost statistical significance (adjusted OR = 1.80; 95% CI: 0.86-3.74). Subgroup analyses suggesting geographical variations in effect magnitude.
conclusionThis study demonstrates differential associations between antenatal exposure to three antidepressant classes (SSRIs, SNRIs, TCAs) and gestational hypertension/preeclampsia risk. Enhanced blood pressure monitoring is advised during SNRI therapy, with clinical decisions requiring individualized risk-benefit assessment. Residual confounding constrains causal inference, necessitating prospective studies with standardized depression scales and systematic exposure documentation to resolve methodological limitations. PROSPERO REGISTRATION: PROSPERO: CRD42025640646.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.